Search Results
Nov 20, 2025, 10:01 ET Genomics Market worth $85.09 billion by 2030 with 12.6% CAGR | MarketsandMarkets™
NGS-based RNA-sequencing Market
More news about: MarketsandMarkets
Nov 20, 2025, 09:55 ET Oxford-Harrington Rare Disease Centre Announces 2025 Scholars Advancing Promising Treatments
Ten scientists selected for second annual award to pursue innovations in gene, RNA, small molecule and cell therapies to treat rare and ultra-rare diseases OXFORD,
More news about: Harrington Discovery Institute
Nov 20, 2025, 09:43 ET ViVac Appoints Keren Leshem as Chief Executive Officer, Strengthening Leadership to Advance RNA-Lipid Nanoparticle Immunotherapy Platform
synthetic biology, RNA innovation and highly effective RNA delivery systems turn cancer into a curable condition." The global cancer immunotherapy market is projected to exceed $125 billion by 2032, with significant growth driven by next-generation RNA-based approaches. ViVac's
More news about: ViVac Pharma Ltd.
Nov 20, 2025, 09:42 ET Oxford-Harrington Rare Disease Centre Announces 2025 Scholars Advancing Promising Treatments
Ten scientists selected for second annual award to pursue innovations in gene, RNA, small molecule and cell therapies to treat rare and ultra-rare diseases OXFORD,
More news about: Harrington Discovery Institute
Nov 20, 2025, 09:00 ET ReviR Therapeutics Receives $4.6 Million CIRM Grant to Advance Huntington's Disease Treatment and Announces Key Development Milestone
the grant's significance: "This CIRM grant is a cornerstone for our targeted approach in treating Huntington's disease. By leveraging our proprietary RNA-targeting technology and our platform VoyageR, this molecule is poised to revolutionize how we treat HD - offering not just symptomatic relief
More news about: ReviR Therapeutics
Nov 20, 2025, 09:00 ET Co-Diagnostics Delivers Address about Tuberculosis Test Adoption and Implementation at The Union World Conference on Lung Health
diagnostics technologies. The Company's technologies are utilized for tests that are designed to detect and/or analyze nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Nov 20, 2025, 09:00 ET IO360º Convenes Technology and Solution Providers to Address Key Capabilities to Advance IO Drug Development
clinical-stage immuno-oncology company, with a primary focus on innovative HSV-1 based oncolytic virus (OV) and mRNA-based (including self-amplifying RNA/saRNA) therapeutics to elicit robust and durable anti-tumor immune response against solid tumors. Voiant leverages
More news about: Immuno-Oncology 360º
Nov 20, 2025, 07:30 ET Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments
after treatment or surgery to help predict cancer recurrence and guide follow-up decisions OncoExTra Test analyzes DNA and RNA from a patient's tumor to guide therapy for advanced, metastatic, or recurrent solid tumors, delivering actionable insights like targetable mutations,
More news about: Abbott
Nov 19, 2025, 17:31 ET KLKB1 Inhibitors Market to Reach New Heights by 2034 Owing to the Launch of Novel Therapies | DelveInsight
attack management through diverse delivery routes such as oral, injectable, and RNA-based formulations. The recent approvals of EKTERLY as the first oral on-demand therapy and DAWNZTERA as the first RNA-based prophylactic, along with NTLA-2002 advancing into Phase III as a gene-editing
More news about: DelveInsight Business Research, LLP
Nov 19, 2025, 10:13 ET Aperture Therapeutics Announces Development Candidate Targeting CD33 to Restore Microglial Homeostasis in FTD and ALS
poor translation in preclinical models, underscoring the need for a more precise RNA-targeting approach," said Martin Jacko, PhD, Founder and CEO of Aperture Therapeutics. "By directly modulating CD33 at the RNA level, APRTX-001 overcomes these historical barriers with a precision approach grounded
More news about: Aperture Therapeutics
Nov 19, 2025, 10:01 ET Hepatitis B and C Therapeutics Market Surges to US$17.02 Billion in 2024 as Innovation, National Screening Policies, and Next-Gen Antivirals Transform Global Care | According to DataM Intelligence
leading manufacturers to stabilize DAA prices through 2027. November 2025: Approval of a new HBV RNA assay under the national testing program, boosting diagnostic accuracy. September 2025: The government
More news about: DataM Intelligence 4 Market Research LLP
Nov 19, 2025, 09:17 ET Accelerating Drug Discovery: Tsingke Biotech Unveils Next-Generation Rapid Protein and Antibody Solutions
comprehensive solutions for research and therapeutic development. With expertise in molecular biology, genetics, and protein science, Tsingke offers custom DNA/RNA synthesis, gene cloning, protein expression, antibody discovery, and viral vector packaging (AAV, LV, AdV). Its production environments, certified with
More news about: Beijing Tsingke Biotech Co., Ltd.
Nov 19, 2025, 09:17 ET Accelerating Drug Discovery: Tsingke Biotech Unveils Next-Generation Rapid Protein and Antibody Solutions
comprehensive solutions for research and therapeutic development. With expertise in molecular biology, genetics, and protein science, Tsingke offers custom DNA/RNA synthesis, gene cloning, protein expression, antibody discovery, and viral vector packaging (AAV, LV, AdV). Its production environments, certified with
More news about: Beijing Tsingke Biotech Co., Ltd.
Nov 19, 2025, 09:13 ET Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44
DIEGO, Nov. 19, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced its Managed Access Program (MAP)
More news about: Avidity Biosciences, Inc.
Nov 19, 2025, 09:00 ET ToolGen Completes U.S. Patent Registration for Core CRISPR Cas9 RNP Technology; Files U.S. Lawsuit Related to CASGEVY®
time and raising safety concerns, including off-target editing. ToolGen's patented approach delivers Cas9 directly as a protein complexed with guide RNA (RNP), avoiding DNA/mRNA-related cytotoxicity, eliminating the risk of foreign DNA insertion, and improving safety through reduced off-target activity.
More news about: ToolGen
Nov 18, 2025, 11:06 ET European Commission Approves BRINSUPRI® (brensocatib) as the First and Only Treatment To Date Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union
early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout
More news about: Insmed Incorporated
Nov 18, 2025, 11:00 ET European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union
early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout
More news about: Insmed Incorporated
Nov 18, 2025, 10:50 ET MiRNA Microarray Kits And Reagents Market Surges to USD 2.45 Billion by 2033, Propelled by 8.5% CAGR - Verified Market Reports®
Global Nucleic Acid Labeling Market Size By Type (DNA Labeling, RNA Labeling), By Labeling (Radioactive Labeling, Fluorescent Labeling), By Application (Diagnostics, Research and Development), By Product Type (Probes,
More news about: Verified Market Reports
Nov 18, 2025, 09:00 ET Zymo Research Announces Strategic Partnership with biomodal to Deliver Next-Gen Multiomic Insights
Known also as The Epigenetics Company, Zymo Research offers a comprehensive range of technologies, including solutions for sample collection, DNA/RNA purification, library preparation, microbiomics, transcriptomics, epigenomics, genomics, and Next-Generation Sequencing (NGS) services.
More news about: Zymo Research Corp.
Nov 18, 2025, 09:00 ET Zymo Research Announces Strategic Partnership with biomodal to Deliver Next-Gen Multiomic Insights
Known also as The Epigenetics Company, Zymo Research offers a comprehensive range of technologies, including solutions for sample collection, DNA/RNA purification, library preparation, microbiomics, transcriptomics, epigenomics, genomics, and Next-Generation Sequencing (NGS) services.
More news about: Zymo Research Corp.
Nov 18, 2025, 09:00 ET Zymo Research gibt strategische Partnerschaft mit biomodal bekannt, um Multiom-Erkenntnisse der nächsten Generation zu liefern
Research, auch bekannt als „The Epigenetics Company", bietet eine umfassende Palette an Technologien, darunter Lösungen für die Probenentnahme, DNA-/RNA-Reinigung, Bibliotheksvorbereitung, Mikrobiomik, Transkriptomik, Epigenomik, Genomik und Next-Generation-Sequencing-Dienstleistungen (NGS).
More news about: Zymo Research Corp.
Nov 18, 2025, 09:00 ET Co-Diagnostics Initiates Clinical Evaluations for Upper Respiratory Multiplex Point-of-Care Test on Co-Dx™ PCR Platform to Support Submission to the U.S. FDA
diagnostics technologies. The Company's technologies are utilized for tests that are designed to detect and/or analyze nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Nov 18, 2025, 05:40 ET Oncology Molecular Diagnostics Market to Reach US$ 6.46 Billion by 2033, Driven by Precision Oncology, and Accelerating Biomarker-Based Therapies - According to DataM Intelligence
targeted therapies focused on KRAS G12C, HER2-low, CLDN18.2, and FGFR mutations. Multi-target RNA-based therapeutics requiring advanced transcriptomic diagnostics for patient stratification. Bispecific
More news about: DataM Intelligence 4 Market Research LLP
Nov 18, 2025, 04:03 ET OCHRE BIO COMPLETES HUMAN LIVER FUNCTIONAL GENOMICS AND SINGLE-CELL DATASETS IN PARTNERSHIP WITH GSK
Ochre Bio is a biotechnology company developing novel RNA medicines for under-treated chronic liver diseases. Its proprietary discovery platform combines machine learning and big human datasets, with in-house RNA chemistry, and testing in live human donor livers. Ochre Bio is headquartered
More news about: Ochre Bio
Nov 18, 2025, 03:00 ET Apriori Bio and A*STAR Infectious Diseases Labs Announce Strategic Partnership to Advance Next Generation Influenza Vaccines
Research Infectious Diseases Labs (A*STAR IDL) announced a strategic research partnership to co-develop and evaluate next generation self-amplifying RNA (saRNA) vaccines targeting seasonal and pandemic influenza. The collaboration brings together Apriori's Octavia™ platform for intelligent, prospective
More news about: Apriori Bio